Pentoxifylline as an ancillary treatment for severe falciparum malaria in Thailand

American Journal of Tropical Medicine and Hygiene

Volumn 58, Issue 3, 1998, Pages 348-353

  Looareesuwan, S ^a   Wilairatana, P ^a   Vannaphan, S ^a   Wanaratana, V ^a   Wenisch, C ^b   Aikawa, M ^c   Brittenham, G ^d   Graninger, W ^b   Wernsdorfer, W H ^e  

^a MAHIDOL UNIVERSITY   (Thailand)

^b UNIVERSITY OF VIENNA   (Austria)

^c TOKAI UNIVERSITY   (Japan)

^d CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; ARTESUNATE; PENTOXIFYLLINE; PLACEBO; TUMOR NECROSIS FACTOR;

ADOLESCENT; ADULT; ARTICLE; BLOOD TRANSFUSION; BRAIN MALARIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HEMODIALYSIS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; JAUNDICE; KIDNEY FAILURE; MALARIA FALCIPARUM; MALE; PARASITEMIA; RANDOMIZED CONTROLLED TRIAL; THAILAND; TREATMENT OUTCOME; UREMIA;

EID: 0031945993     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.1998.58.348     Document Type: Article

References (34)

1. Grau GE, Taylor TE, Molyneux ME, Wirima JJ, Vassalli P, Hommel M, Lamert PH, 1989. Tumor necrosis factor and disease severity in children with falciparum malaria, N Engl J Med 320: 1586-1591.
2. Kern P, Hemmer CJ, van Damme J, Gruss HJ, Dietrich M, 1989. Elevated tumor necrosis factor alpha and interleukin-6 serum levels as markers for complicated Plasmodium falciparum malaria. Am J Med 57: 139-143.
3. Kwiatkowski D, Hill AVS, Sambou I, Twumasi P, Castracane J, Manogue KR, Cerami A, Brewster DR, Greenwood BM, 1990. TNF concentration in fatal cerebral, non-fatal cerebral, and uncomplicated Plasmodium falciparum malaria. Lancet 336: 1201-1204.
4. Tracey KJ, Vlassara H, Cerami A, 1989. Cachectin/tumour necrosis factor. Lancet i: 1122-1126.
5. Berendt AR, Simmons DL, Tansey J, Newbold CI, Marsh K, 1989. Intercellular adhesion molecule-1 is an endothelial cell adhesion receptor for Plasmodium falciparum. Nature 341: 57-59.
6. Clark IA, 1987. Cell-mediated immunity in protection and pathology of malaria. Parasitol Today 3: 300-305.
7. Sullivan GW, 1988. Inhibition of the inflammatory action of interleukin-1 and tumor necrosis factor (alpha) on neutrophil function with pentoxifylline. Infect Immun 56: 1722-1729.
8. Zabel P, 1989. Oxipentifylline in endotoxinaemia. Lancet ii: 1474-1477.
9. Grunfeld C, 1990. Tumor necrosis factor: immunological, antitumor, metabolic, and cardiovascular activities. Adv Intern Med 35: 45-72.
10. Strieter RM, 1988. Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxifylline. Biochem Biophys Res Comm 155: 1230-1236.
11. Smedly LA, 1986. Neutrophil-mediated injury to endothelial cells. J Clin Invest 77: 1233-1243.
12. Stephens KE, 1988. TNF causes increased pulmonary permeability and edema. Am Rev Resp Dis 137: 1364.
13. Lilly CM, 1988. Pentoxifylline prevents TNF-induced acute lung injury. Am Rev Resp Dis 139: 1361.
14. Pitel JA, 1978. Pentoxifylline in the combination therapy of pyelonephritis. Pharmatherapeutica 2 (suppl 1): 138-140.
15. Brunner LJ, 1989. Prevention of cyclosporine-induced nephro-toxicity with pentoxifylline. Ren Fail 11: 97-104.
16. Graninger W, 1991. Pentoxifylline in cerebral malaria (correspondence), J Infect Dis 164: 829.
17. Kremsner PG, 1991. Pentoxifylline prevents murine cerebral malaria. J Infect Dis 164: 605-608.
18. Leonhardt H, 1977. Effects of pentoxifylline on red cell deformability under hyperosmolar conditions. Naunyn-Schmiedebergs Arch Pharmacol 299: 197-200.
19. Ehrly AM, 1975. The effect of pentoxifylline on the flow properties of hyperosmolar blood. IRCS Med Sci 3: 465.
20. Seiffge D, 1982. Effect of pentoxifylline on red cell aggregation (RCA). IRCS Med Sci 8: 727.
21. Di Perri G, Di Perri GH, Monterio BG, Bonora S, Hennig C, Cassatella M, Micciolo R, Vento S, Bassetti D, Concia BE, 1995. Pentoxifylline as a supportive agent in the treatment of cerebral malaria in children. J Infect Dis 171: 1317-1322.
22. Warrell DA, Molyneux ME, Beales PF, 1990. Severe and complicated malaria. Second edition. Trans R Soc Trop Med Hyg 84 (suppl 2): 1-65.
23. World Health Organization, 1973. Advances in malaria chemotherapy. World Health Organ Tech Rep Ser 529: 30-35.
24. Wenisch C, Looareesuwan S, Wilairatana P, Parschalk B, Vannapann S, Wanaratana V, Wernsdorfer W, Graninger W, 1998. Effect of pentoxifylline on cytokine patterns in the therapy of complicated Plasmodium falciparum malaria. Am J Trop Med Hyg 58: 343-347.
25. Warrell DA, Looareesuwan S, Warrell MJ, Kasemsarn P, Intaraprasert R, Bunnag D, Harinasuta T, 1982. Dexamethasone proves deleterious in cerebral malaria: a double-blind study in 100 comatose patients. N Engl J Med 306: 313-319.
26. Punyagupta S, Srichaikul T, Nitiyanant P, Petchlai B, 1974. Acute pulmonaty insufficiency in falciparum malaria: summary of 12 cases with evidence of disseminated intravascular coagulation. Am J Trop Med Hyg 23: 551-559.
27. Bunnag D, Viravan C, Looareesuwan S, Karbwang J, Harinasuta T, 1991. Clinical trial of artesunate and artemether on multidrug resistant falciparum malaria in Thailand: a preliminary report. Southeast Asian J Trop Med Public Health 22: 380-388.
28. Looareesuwan S, Viravan S, Vanijanonta S, Wilairatana P, Suntharasamai P, Charoenlarp P, Arnold K, Kyle DE, Canfield C, Webster K, 1992. A randomised trial of mefloquine, artesunate and artesunate followed by mefloquine in acute uncomplicated falciparum malaria. Lancet i: 821-824.
29. Grau GE, Fajardo LF, Piguet PF, Allet B, Lambert PH, Vassali R 1987. Tumor necrosis factor (Cachectin) as an essential mediator in murine cerebral malaria. Science 237: 1210-1212.
30. Kwiatkowski D, Molyneux ME, Stephens S, Curtis N, Klein N, Pointaire P, Smit M, Allan R, Brewster DR, Grau GE, Greenwood BM, 1993. Anti-TNF therapy inhibits fever in cerebral malaria. Q J Med 86: 91-98.
31. McGuire W, Hiel AVA, Allsopp GEM, Greenwood BM, Kwiatkowski D, 1994. Variation in the TNFα promoter region associated with susceptibility to cerebral malaria. Nature 371: 508-511.
32. van Hensbroek MB, Palmer A, Onyiorah E, Schneider G, Jaffar S, Dolan G, Memming H, Frenkel J, Enwere G, Bennett S, Kwiatkowski D, Greenwood B, 1996. The effect of a monoclonal antibody to tumor necrosis factor on survival from childhood cerebral malaria. J Infect Dis 174: 1091-1097.
33. Hien TT, Phu NH, Mai NTH, Chau TTH, Trang TTH, Loc P, Chong BM, Dung NT, Vinh H, Waller DJ, White NJ, 1992. An open randomised comparison of intravenous and intramuscular artesunate in severe malaria. Trans R Soc Trop Med Hyg 86: 584-585.
34. Kwiatkowski D, Bate C, 1995. Inhibition of tumour necrosis factor (TNF) production by antimalarial drugs used in cerebral malaria. Trans R Soc Trop Med Hyg 89: 225-216.